Literature DB >> 30452959

Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies.

Ashley B Pitcher1, Annick Borquez2, Britt Skaathun2, Natasha K Martin3.   

Abstract

In 2016, the World Health Organization issued global elimination targets for hepatitis C virus (HCV), including an 80% reduction in HCV incidence by 2030. The vast majority of new HCV infections occur among people who inject drugs (PWID), and as such elimination strategies require particular focus on this population. As governments urgently require guidance on how to achieve elimination among PWID, mathematical modeling can provide critical information on the level and targeting of intervention are required. In this paper we review the epidemic modeling literature on HCV transmission and prevention among PWID, highlight main differences in mathematical formulation, and discuss key insights provided by these models in terms of achieving WHO elimination targets among PWID. Overall, the vast majority of modeling studies utilized a deterministic compartmental susceptible-infected-susceptible structure, with select studies utilizing individual-based network transmission models. In general, these studies found that harm reduction alone is unlikely to achieve elimination targets among PWID. However, modeling indicates elimination is achievable in a wide variety of epidemic settings with harm reduction scale-up combined with modest levels of HCV treatment for PWID. Unfortunately, current levels of testing and treatment are generally insufficient to achieve elimination in most settings, and require further scale-up. Additionally, network-based treatment strategies as well as prison-based treatment and harm reduction provision could provide important additional population benefits. Overall, epidemic modeling has and continues to play a critical role in informing HCV elimination strategies worldwide.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Epidemic modeling; Hepatitis c virus; Infectious disease; People who inject drugs; Public health; Transmission

Mesh:

Year:  2018        PMID: 30452959      PMCID: PMC6522340          DOI: 10.1016/j.jtbi.2018.11.013

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  78 in total

1.  A computer model of the spread of hepatitis C virus among injecting drug users.

Authors:  D Mather; N Crofts
Journal:  Eur J Epidemiol       Date:  1999-01       Impact factor: 8.082

2.  The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis.

Authors:  Jisoo A Kwon; Jenny Iversen; Lisa Maher; Matthew G Law; David P Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-01       Impact factor: 3.731

3.  Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs.

Authors:  Irmgard Zeiler; Trevor Langlands; John M Murray; Alison Ritter
Journal:  Drug Alcohol Depend       Date:  2010-04-28       Impact factor: 4.492

4.  Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.

Authors:  P Vickerman; M Hickman; A Judd
Journal:  Int J Epidemiol       Date:  2007-01-11       Impact factor: 7.196

Review 5.  Global epidemiology of hepatitis C virus infection.

Authors:  Colin W Shepard; Lyn Finelli; Miriam J Alter
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

Review 6.  Substance abuse and dependence in prisoners: a systematic review.

Authors:  Seena Fazel; Parveen Bains; Helen Doll
Journal:  Addiction       Date:  2006-02       Impact factor: 6.526

7.  The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users.

Authors:  John M Murray; Matthew G Law; Zhanhai Gao; John M Kaldor
Journal:  Int J Epidemiol       Date:  2003-10       Impact factor: 7.196

8.  A nested-epidemic model for the spread of hepatitis C among injecting drug users.

Authors:  Nicolino Esposito; Carla Rossi
Journal:  Math Biosci       Date:  2004 Mar-Apr       Impact factor: 2.144

9.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais; Corina Lelutiu-Weinberger
Journal:  Am J Epidemiol       Date:  2008-10-09       Impact factor: 4.897

10.  Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan.

Authors:  P Vickerman; L Platt; S Hawkes
Journal:  Sex Transm Infect       Date:  2009-04       Impact factor: 3.519

View more
  13 in total

1.  Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs.

Authors:  Elana S Rosenthal; Rachel Silk; Poonam Mathur; Chloe Gross; Rahwa Eyasu; Laura Nussdorf; Kristi Hill; Christopher Brokus; Aaron D'Amore; Nadeera Sidique; Phyllis Bijole; Miriam Jones; Randy Kier; Dana McCullough; David Sternberg; Kristen Stafford; Junfeng Sun; Henry Masur; Shyamasundaran Kottilil; Sarah Kattakuzhy
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

2.  Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment.

Authors:  Sarah Brothers; Elizabeth DiDomizio; Lisa Nichols; Ralph Brooks; Merceditas Villanueva
Journal:  AIDS Behav       Date:  2022-07-01

3.  Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges.

Authors:  Blessing Dzingirai; Leolin Katsidzira; Celia Moffat Joel Matyanga; Maarten Jacobus Postma; Marinus van Hulst; Nyashadzaishe Mafirakureva
Journal:  J Viral Hepat       Date:  2021-04-09       Impact factor: 3.728

Review 4.  A review of network simulation models of hepatitis C virus and HIV among people who inject drugs.

Authors:  Meghan Bellerose; Lin Zhu; Liesl M Hagan; William W Thompson; Liisa M Randall; Yelena Malyuta; Joshua A Salomon; Benjamin P Linas
Journal:  Int J Drug Policy       Date:  2019-11-15

5.  Hepatitis C virus modelled as an indirectly transmitted infection highlights the centrality of injection drug equipment in disease dynamics.

Authors:  Miles D Miller-Dickson; Victor A Meszaros; Salvador Almagro-Moreno; C Brandon Ogbunugafor
Journal:  J R Soc Interface       Date:  2019-09-04       Impact factor: 4.118

6.  Hepatitis C Virus Transmission Clusters in Public Health and Correctional Settings, Wisconsin, USA, 2016-20171.

Authors:  Karli R Hochstatter; Damien C Tully; Karen A Power; Ruth Koepke; Wajiha Z Akhtar; Audrey F Prieve; Thomas Whyte; David J Bean; David W Seal; Todd M Allen; Ryan P Westergaard
Journal:  Emerg Infect Dis       Date:  2021-02       Impact factor: 6.883

7.  State estimation-based control of COVID-19 epidemic before and after vaccine development.

Authors:  Arman Rajaei; Mahsa Raeiszadeh; Vahid Azimi; Mojtaba Sharifi
Journal:  J Process Control       Date:  2021-04-12       Impact factor: 3.666

8.  Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis.

Authors:  Ximena A Levander; Taylor A Vega; Andrew Seaman; P Todd Korthuis; Honora Englander
Journal:  Subst Abus       Date:  2021-06-23       Impact factor: 3.716

9.  Utilising an access to care integrated framework to explore the perceptions of hepatitis C treatment of hospital-based interventions among people who use drugs.

Authors:  Ximena A Levander; Taylor A Vega; Andrew Seaman; P Todd Korthuis; Honora Englander
Journal:  Int J Drug Policy       Date:  2021-07-03

10.  Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region.

Authors:  Jacqueline E Sherbuk; Terry Kemp Knick; Chelsea Canan; Patrice Ross; Bailey Helbert; Eleanor Sue Cantrell; Charlene Joie Cantrell; Rachel Stallings; Nicole Barron; Diana Jordan; Kathleen A McManus; Rebecca Dillingham
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.